Clinical trials: Pneumococcal Infectious Disease
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infectious Diseases
A Lot-to-Lot Consistency Clinical Trial of PCV13
A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years.
- Trial name
- NCT07832500
- Testing
- Sinovac PCV13 lot 1, Sinovac PCV13 lot 2, Sinovac PCV13 lot 3
- Where
- China
- Volunteers
- 1,125 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Disease
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13.
- Trial name
- NCT05408429
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 43 sites in Hungary, Poland and 1 more
- Volunteers
- 356 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Vaccines, Pneumococcal Infections
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
The goal of this clinical trial is to evaluate the immunogenicity and safety of Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT/TT) as compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine…
- Trial name
- NCT06608199
- Testing
- pneumococcal disease prevention
- Where
- 3 sites in Indonesia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
HIV Infections
Study of Anti-HIV Therapy Intensification
The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe.
- Trial name
- NCT00034086
- Testing
- Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
- Trial name
- NCT03574389
- Testing
- 13vPnC, Hib
- Where
- 2 sites in China
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infection
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae.
- Trial name
- NCT07300267
- Testing
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1)
- Where
- 15 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC